R. Yelin et S. Schuldiner, THE PHARMACOLOGICAL PROFILE OF THE VESICULAR MONOAMINE TRANSPORTER RESEMBLES THAT OF MULTIDRUG TRANSPORTERS, FEBS letters, 377(2), 1995, pp. 201-207
Vesicular neurotransmitter transporters function in synaptic vesicles
and other subcellular organelles and they were thought to be involved
only in neurotransmitter storage, Several findings have led us to test
novel aspects of their function, Cells expressing a c-DNA coding for
one of the rat monoamine transporters (VMAT1) become resistant to the
neurotoxin N-methyl-4-phenylpyridinium (MPP(+)) [Liu et al. (1992) Cel
l, 70, 539-551]. The basis of the resistance is the VMAT1-mediated tra
nsport and sequestration of the toxin into subcellular compartments. I
n addition, the deduced sequence of VMAT1 predicts a protein that show
s a distinct homology to a class of bacterial drug resistance transpor
ters (TEXANs) that share some substrates with mammalian multidrug resi
stance transporters (MDR) such as the P-glycoprotein. These findings i
nduced us to test whether compounds that are typically transported by
MDR interact also with vesicular transporters, The use of [H-3]reserpi
ne binding to determine drug interactions with VMAT allowed assessment
of the ability of various drugs to bind to the substrate site of the
transporter, Cytotoxic compounds such as ethidium, isometamidium, tetr
aphenylphosphonium, rhodamine, tacrine and doxorubicin, interact speci
fically with vesicular monoamine transporters, Verapamil, a calcium ch
annel blocker, is also a competitive inhibitor of transport, Tn the ca
se of rhodamine, fluorescence measurements in digitonin-permeabilized
cells demonstrated ATP-dependent VMAT-mediated transport, The results
imply that even though the bacterial and vesicular transporters are st
ructurally different from the P-glycoprotein, they share a similar sub
strate range, These findings suggest a novel possible way of protectio
n from the effects of toxic compounds by removal to subcellular compar
tments.